Douglas Swirsky serves as the Chief Financial Officer (CFO) at MaxCyte, Inc., a leading provider of cell engineering platforms. With a robust background in finance and strategic planning, Swirsky has been instrumental in guiding MaxCyte through significant growth phases. Prior to joining MaxCyte, he held the position of CFO at Hyperion Catalysis International, where he was pivotal in driving the company's financial strategy and operational efficiency. His career also includes a notable tenure at Thermo Fisher Scientific, where he honed his skills in corporate finance and business development, contributing to the company's expansion efforts. At MaxCyte, Swirsky's role encompasses overseeing the company's financial operations, including budgeting, forecasting, and investor relations. His strategic foresight has been crucial in navigating the complexities of the life sciences industry, particularly in scaling MaxCyte's innovative cell engineering technologies. Under his leadership, MaxCyte has successfully secured significant funding and partnerships, enhancing its market position and enabling the company to advance its mission of revolutionizing cell-based therapies. Swirsky's expertise in financial management and his commitment to fostering sustainable growth have made him an invaluable asset to MaxCyte's executive team.